Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Predictors of Hemorrhagic Events in Patients with Myocardial Infarction complicated by Cardiogenic Shock Undergoing Dual Antiplatelet Therapy
Session:
SESSÃO DE POSTERS 37 - DOENÇAS CARDIOVASCULARES - TERAPÊUTICA ANTITROMBÓTICA
Speaker:
Samuel Azevedo
Congress:
CPC 2025
Topic:
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
Theme:
14. Acute Cardiac Care
Subtheme:
14.4 Acute Cardiac Care – Cardiogenic Shock
Session Type:
Cartazes
FP Number:
---
Authors:
Samuel Azevedo; Márcia Presume; João Presume; Débora Silva Correia; Rita Barbosa Sousa; Ana Rita Bello; Rita Almeida Carvalho; Catarina Brízido; Christopher Strong; Manuel Sousa Almeida; Jorge Ferreira; António Tralhão
Abstract
<p style="text-align:start"><span style="font-size:12px"><span style="font-family:Arial,Helvetica,sans-serif"><span style="color:#000000"><strong>Introduction: </strong>Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) is associated with considerable morbidity and mortality. Despite advancements in the management of these patients, bleeding complications remain prevalent and represent a critical challenge in this clinical context.</span></span></span></p> <p style="text-align:start"><span style="font-size:12px"><span style="font-family:Arial,Helvetica,sans-serif"><span style="color:#000000"><strong>Objective: </strong>To evaluate the incidence, etiology, and predictors of hemorrhagic events in AMI-CS patients treated with dual antiplatelet therapy (DAPT).</span></span></span></p> <p style="text-align:start"><span style="font-size:12px"><span style="font-family:Arial,Helvetica,sans-serif"><span style="color:#000000"><strong>Methods: </strong>A retrospective analysis was performed on 154 patients with AMI-CS admitted to a cardiac intensive care unit between January 2017 and October 2024. Baseline demographics, clinical characteristics, bleeding events, and transfusion requirements were collected. Major bleeding events were defined according to Bleeding Academic Research Consortium (BARC) criteria, class ≥3. Univariate logistic regression analysis was used to identify predictors of hemorrhagic events, including demographic, clinical, laboratory, and procedural variables.</span></span></span></p> <p style="text-align:start"><span style="font-size:12px"><span style="font-family:Arial,Helvetica,sans-serif"><span style="color:#000000"><strong>Results: </strong>The cohort had a median age of 67 years, with 65.6% male. The most prevalent comorbidities included hypertension (74%), diabetes mellitus (44.2%), and dyslipidemia (63%).</span></span></span></p> <p style="text-align:start"><span style="font-size:12px"><span style="font-family:Arial,Helvetica,sans-serif"><span style="color:#000000">Major bleeding events occurred in 29.2% of patients, with BARC3A (figure 1) and access-site hemorrhages (figure 2) accounting for 50.9% and 37.5%, respectively. Patients experiencing major bleeding events frequently required red blood cell transfusions, with 43.4% receiving more than four units (figure 3).</span></span></span></p> <p style="text-align:start"><span style="font-size:12px"><span style="font-family:Arial,Helvetica,sans-serif"><span style="color:#000000">Independent predictors included lower minimum platelet count [(for each 1 × 10*9/L decrease in platelet count, OR 0.986 (95% CI: 0.979–0.993; p < 0.001)], the use of mechanical circulatory support (OR: 5.517; 95%CI: 2.602-11.697 p<0.001) and renal replacement therapy (OR: 2.906; 95%CI:1.285-6.571 p=0.010). Antithrombotic therapy with glycoprotein IIb/IIIa inhibitors (OR: 6.729; 95%CI: 2.183-20.745 p<0.001) and anticoagulants (OR: 2.246; 95%CI: 1.049-4.806 p=0.037) were strongly associated with an increased risk of major bleeding. The choice of ticagrelor (29.9%) [vs clopidogrel (70.1%]) was not identified as a significant predictor of hemorrhagic events (figure 4).</span></span></span></p> <p style="text-align:start"><span style="font-size:12px"><span style="font-family:Arial,Helvetica,sans-serif"><span style="color:#000000"><strong>Conclusion: </strong>Hemorrhagic events are common in AMI-CS patients on DAPT, influenced by preexisting conditions and procedural factors. Antithrombotic therapy with glycoprotein IIb/IIIa inhibitors and anticoagulants significantly increased risk, underscoring the need for tailored strategies to manage bleeding in this high-risk population.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site